The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Analysis of tisagenlecleucel in B-cell NHL in BELINDA
Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, presents findings from the Phase III BELINDA (NCT03570892) trial of tisagenlecleucel (tisa-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, with the aim of moving tisa-cel to second-line therapy from third-line therapy. The primary endpoint of event-free survival was not met, despite other CAR T-cell therapies having success in similar trials. Further analysis of the trial design will elucidate the causes of the results and Dr Westin highlights the practicality of tisa-cel in its current indications. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
